FDG-PET has recently emerged as an important tool for the management of Hodgkins lymphoma. Although its use for initial staging and response evaluation at the end of treatment is well established, the place of interim PET for response assessment and subsequent treatment tailoring is still quite controversial. The use of interim PET after a few cycles of chemotherapy may allow treatment reductio...

E-mail: [email protected] Abstract Introduction: Plasmablastic lymphoma, a rare and aggressive form of Non-Hodgkins lymphoma, rarely presents as a retroperitoneal mass. There are no case reports in the literature of plasmablastic lymphoma presenting in living, HIV-negative patient status post liver transplantation. Presentation of Case: We report the case of a 63 year-old HIV-negative mal...

A 66-year-old man, seen in 1971 after a presyncopal episode, was found to have a heart rate of 32 beats per minute. His ECG showed complete heart block with narrow QRS complexes. After two Adams-Stokes attacks in hospital a temporary pacemaker was inserted. He had previously been well with no history of tuberculosis nor of contact with tuberculosis. Investigation showed no evidence of myocardia...

In the present report we demonstrate that the IL-6 gene is expressed in anti-Ig-activated and neoplastic B cells. After activation with anti-Ig, splenic B cells rapidly expressed IL-6 mRNA with peak expression occurring at 4 h and declining rapidly thereafter. In an attempt to exclude that the IL-6 mRNA expression was in non-B cells, T cells and monocytes were extensively depleted. In this high...

BACKGROUND While the incidence of non-Hodgkins lymphoma (NHL) has been rising worldwide, the reasons remain undefined. Recent research has focused on effect of red andf processed meat intake as a risk factor, but with inconclusive results. We therefore conducted a meta-analysis of data published to date, to ascertain the overall association between intake and NHL. MATERIALS AND METHODS A publ...

From July 1971 to August 1975, 63 previously untreated patients with stage IV non-Hodgkin's lymphomas with favorable histologies were prospectively randomized to three treatment programs: cyclophosphamide, vincristine, and prednisone alone (CVP); split course CVP and total lymphoid irradiation (CVP-TLI); or single alkylating agent (SA) therapy. More than 95% of all patients responded to therapy...